It doesn't have enough ratings yet to judge what users think.
ImmerseRx mNSCLC Immunotherapy is made and published by
Deborah Wood Associates, Inc.
AppBrain is an independent app data site and isn't affiliated with Deborah Wood Associates, Inc.
The app name, icon, screenshots and description belong to Deborah Wood Associates, Inc and are shown as
published on the App Store.
About ImmerseRx mNSCLC Immunotherapy
ImmerseRx mNSCLC Immunotherapy was a medical app developed by Deborah Wood Associates, Inc. It was removed from the App Store Nov 23, 2024.
User Ratings
ImmerseRx mNSCLC Immunotherapy was rated 5.00 out of 5 stars, based on one rating ratings.
App Information
ImmerseRx mNSCLC Immunotherapy was free. The app size was 197.75 MB. The last available version was 1.0.1. The last update was on December 13, 2022.
Technical Requirements
The app had a content rating of High Maturity. The app had been available on the App Store since November 2022.
Description by Deborah Wood Associates, Inc(from the App Store)
Powered by Forefront Collaborative, ImmerseRx mNSCLC Immunotherapy is an interactive learning tool that explores tumor immune evasion pathways in metastatic non-small cell lung cancer (mNSCLC), such as the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, and how immunotherapy targets these pathways to lead to tumor cell death. Moving through four interactive scenes, users will also learn about biomarker testing that is necessary to inform treatment decisions around immunotherapy for mNSCLC.
Pinch in and zoom out to scale, rotate, raise, or lower the models; and walk around the 3D objects to view animations up close. This app was created for medical oncologists, oncology nurse practitioners and physician assistants, pulmonologists, pathologists, and other healthcare professionals who are involved in the care of patients with mNSCLC.
This app is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Note: after the creation of this app, additional immunotherapy combinations were approved as first-line treatment options for mNSCLC: cemiplimab plus platinum-based chemotherapy and tremelimumab plus durvalumab plus platinum-based chemotherapy.
Each subscription will automatically renew 3 days before the expiration date for
the same time period. Subscriptions can be cancelled at any time before the renewal.
![Multiple Myeloma [MM] icon](https://is1-ssl.mzstatic.com/image/thumb/Purple211/v4/d2/65/32/d26532b6-e51d-2535-7441-a7554afcac41/AppIcon-0-0-1x_U007epad-0-11-0-85-220.png/100x100bb.jpg)
